The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Webcasts|August 10, 2020
Site-Centric Clinical Platforms Are Better for Sponsors
Author(s)Cognizant
Come listen to how peers were able to improve site performance by consolidating access to different clinical technologies. Join us during a webcast to discuss how to alleviate your sites’ operational inefficiencies and administrative challenges via a centralized platform. Live: Wednesday, Aug. 26, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Aug. 26, 2021.
Register free:
Event Overview:
Site-centric clinical platforms deliver greater operational efficiencies and accelerated timelines across clinical trials. Discover how 7 of the top 15 global biopharmaceutical companies came together on a single clinical technology platform and operate through common workflows and leverage common trial documents. In turn, find out how this environment helps sites and investigators stay at the center of this ecosystem.
Key Learning Objectives:
- Hear about site and sponsor experiences and how they have leveraged the cloud-based solution in addition to what efficiencies they’ve discovered
- Identify how harmonized management of key components of clinical trials across industry stakeholders can improve clinical trial timelines
- Identify how to facilitate sponsor and site collaboration on key clinical trial documents, enabling seamless workflow and document exchange between site and sponsor TMF systems reducing the burden on both study teams and sites
Speakers: Larissa Comis, Product Lead, Shared Investigator Platform,Cognizant Life Siences
Dr. Lestter Cruz Serrano, Medical Affairs Advisor,Cognizant Life Sciences
Hobs Apell, Senior Executive Director, Clinical Trials Office, KUCC
Time and date: Wednesday, Aug. 26, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Aug. 26, 2021.
Sponsor: Cognizant
Register free:
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5